Xcout Intel
Tune Therapeutics
Tune Therapeutics, Inc. is a biotechnology company founded in 2020 that develops advanced genomic and epigenetic therapies, including epigenetic silencers.
Subscribe to see Tune Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tune Therapeutics at a glance
Tune Therapeutics is a biotechnology company headquartered in United States. It has raised at least $357.4M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series B, raised $175M in January 2025. Xcout tracks 13 named people at Tune Therapeutics, including John McHutchison (CEO, Chairman of the Board).
Tune Therapeutics leadership
- John McHutchisonCEO, Chairman of the Board
- Derek JantzChief Scientific Officer
- Heidi ZhangChief Development Officer
- Akira MatsunoCo-Founder, President, CFO, COO
- Charles GersbachCo-Founder
- Dan McHughCo-Founder, Investor
7 more named people on record for Tune Therapeutics, with roles, board committees and tenure — see the full roster →
Tune Therapeutics funding rounds
At least $357.4M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $175M | 4 named | |
| SEC Form D filing | $182.4M | — | |
| — | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Tune Therapeutics competitors
A few of Tune Therapeutics's closest competitors — see the full list of competitors and alternatives →
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.
Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Get Tune Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Tune Therapeutics in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access